Ghrelin is a well-known peptide that can significantly influence the release of growth hormone (GH) from the pituitary gland, unfortunately Ghrelin has also been dubbed ‘the hunger hormone’ since its use can trigger hunger pains.
However, now there is an analogue of Ghrelin called GHRP2 (growth hormone releasing peptide II) that still stimulates the production of GH, but without any significant side effects of causing the desire to eat.
The growth hormone releasing peptides (including sermorelin) have been advocated by physicians such as Richard Walker, M.D., Ph.D., since they offer a number of advantages over injecting GH itself, these being:
GHRP2 has been studied* in 94 volunteers aged between 40 and 70 years. Over a period of 90-days the subjects consumed 10ml of GHRP2 in the morning. Their average IGF-1 levels (a measure of GH in the blood) was 103.54ng/ml and rose to an average of 120.47ng/ml by the end of the period.
Other measures taken before and after included total body fat which decreased on average by 9.14% with visceral fat levels decreasing on average by 14.27% (with no significant changes in the placebo group). At the same time, muscle mass (as lean body mass) increased on average by 5.37% in the GHRP2 group; plus, forced lung capacity was increased on average by 16.61% (and again there no significant changes in the placebo group).
At the same time improvements were also noted to the patients waist and hips and ratios, total body composition (fat, water, bone and muscle mass), and forced lung capacity.
All these positive changes to these aging biomarkers corroborate findings from the studies that utilized GH injections. Therefore it is proof that GHRPs offer a real world alternative to GH injections.
Dr. Walker has gone on record to state that Sermorelin taken at bedtime (which enhances the release of GH into the bloodstream) and GHRP2 taken first thing AM (which increases production of GH), when combined can offer a 5-fold efficacy. Therefore these two agents (used sublingually and orally respectively) can be considered to be extremely synergistic.
Few side effects have been noted in the studies, some experience soft stools and upset stomachs. There have also been increases in the total blood platelet count, but values have remained within the normal clinical range.
The toxicity and LD50 ratios for GHRP2 also look good and therefore when used within its normal clinical dose ranges should not present any problems.
GHRP2 can be taken up to 10ml first thing in the AM. This may be advocated when the patient needs to significantly raise their GH levels to achieve results as achieved in the study mentioned above. However once levels and results are confirmed, the daily maintenance dose is recommended at 4ml.
*A phase III, randomized, open label, placebo controlled clinical study to evaluate the efficacy and safety of GHRP2 for the treatment of age related changes in form, function and quality of life in healthy subjects. Date on file, ProSoma FLA, 2 March, 2012.